Request a document copy: Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Requester name:

Requester e-mail:

Files:

all files (of this document) in restricted access

the file(s) you requested

Message:

Cancel Send